The first once-daily oral treatment1
For people living with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor is KRAS G12C positive, and who have received at least one prior treatment.2
LUMAKRAS™ is a trademark of Amgen Inc.
Reference: 1. LUMAKRAS™ (sotorasib) Prescribing Information. Thousand Oaks, CA: Amgen; 2021. 2. LUMAKRAS™ (sotorasib) Patient Information. Thousand Oaks, CA: Amgen 2021.